ACADIA PharmaceuticalsNASDAQ: ACAD

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide). “These interim data from the LOTUS s.

Let's examine five pharmaceutical companies, PRGO, IOVA, VTRS, TEVA, and ACAD, that are preparing to announce their earnings this week.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has granted 10 academic scholarships to recipients of the inaugural Rett Sibling Scholarship program. Established in 2023, the program aims to support siblings of individuals with Rett syndrome. Each recipient will receive $5,000 for the 2024-25 academic year to further their higher education goals.

In April, it may be advisable to sell certain pharmaceutical stocks due to the high risk involved in holding onto these companies, particularly with the industry facing greater regulatory scrutiny and pricing challenges.

Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.

Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.

Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.

Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.